Results 101 to 110 of about 12,211 (152)

Current Perspectives on JC Polyomavirus Transmission and Associated Diseases: Implications for Prevention in Risk Populations. [PDF]

Viruses
Oliveira JM, Luxo C, Matos AAM.
europepmc   +1 more source

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis. [PDF]

Neurol Ther
Chisari CG, Crimì P, Spampinato G, Ferraro E, Alecci A, Lo Fermo S, Cimino V, Zappia M, Patti F.   +8 more
europepmc   +1 more source

Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis. [PDF]

Ther Adv Neurol Disord
Ebne-Ali-Heydari Y, Ramezani A, Jozayi A, Norouzi M, Zohrabi P, Kaveyee H.   +5 more
europepmc   +1 more source

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. [PDF]

Eur J Neurol
Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, Schäfer J, Weglewski A, Romani KQ, Jensen HB, Illes Z, Papp V, Sejbaek T, Poulsen MB, Kant M, Torring CW, Sellebjerg F, Magyari M, DMSG Group.   +18 more
europepmc   +1 more source

Progressive multifocal leukoencephalopathy - a diagnostic guide for the clinical neurologist. [PDF]

Front Neurol
Jia DT.
europepmc   +1 more source

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study. [PDF]

Neurotherapeutics
Brummer T, Räuber S, Jakob J, Willison AG, Schraad M, Protopapa M, Fleischer MI, Boeckers JM, Ruck T, Meuth SG, Zipp F, Fleischer V, Bittner S.   +12 more
europepmc   +1 more source

Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives. [PDF]

Neurol Ther
Preziosa P, Guido G, Filippi M, Rocca MA.   +3 more
europepmc   +1 more source

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center. [PDF]

Arq Neuropsiquiatr
Simon-Nogueira AB, Holanda AC, Rosalem RA, Santillan TIV, Silva GD, Apostolos-Pereira SL, Adoni T, Callegaro D, Spricigo MG, Oliveira MB.   +9 more
europepmc   +1 more source

Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis. [PDF]

Neurol Sci
Maal AB, Arki MK, Nabavi SM, Rezaei-Tavirani M, Rismani E, Vosough M, Azizi G, Hossein-Khannazer N.   +7 more
europepmc   +1 more source